D-0860-2022 Class II Terminated

Recalled by Mylan Institutional, Inc. (D.B.A. UDL Laboratories) — Rockford, IL

FDA drug recall D-0860-2022 was initiated by Mylan Institutional, Inc. (D.B.A. UDL Laboratories) on Apr 1, 2022 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: OOS result was obtained for Any Other Individual Impurity at the 12M room temperature time point. The recall status is terminated (terminated Jun 9, 2023). Affected quantity: 555 cartons.

Recall details

Product Type
Drugs
Report Date
May 18, 2022
Initiation Date
Apr 1, 2022
Termination Date
Jun 9, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
555 cartons

Product description

Esomeprazole Magnesium Delayed-Release Capsules, USP 20 mg, packaged in Unit Dose Blister Cards of 6 (10 cards of 6 Capsules each per carton), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC 42292-009-16

Reason for recall

Failed Impurities/Degradation Specifications: OOS result was obtained for Any Other Individual Impurity at the 12M room temperature time point.

Distribution pattern

Nationwide within USA

Code information

Lot #: 3112743, Exp. Date 4/30/2023; 3112582, Exp. Date 3/31/2023; 3110438, 3111708, 3111120, Exp. Date 7/31/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0860-2022
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0860-2022. Report a data issue: hello@regdatalab.com.